Our ambition is to develop Spexis into a leading biopharmaceutical company with a strategic focus on rare diseases, oncology and antimicrobial resistance. We have two clinical programs focused on products for rare, chronic respiratory diseases.

Cooperation possibilities

Spexis is a clinical-stage biopharmaceutical company based in Allschwil, Switzerland focused on rare diseases and oncology. The current pipeline of the company is a combination of two legacy companies, Polyphor and EnBiotix, which merged in December 2021.

Facts & figures
  • Type of organization
    Public company
  • Year of foundation
  • Number of employees in Switzerland
Key business

You may also be interested in